Acquired vulvar lymphangioma: risk factors, disease associations, and management considerations: a systematic review

• Main Authors: Amber Duong, BS (Author), Alex Balfour, BS (Author), Christina N. Kraus, MD (Author)
• Format: Book
• Published: Wolters Kluwer, 2023-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2352-6475; 10.1097/JW9.0000000000000087
• Keywords: Dermatology; RL1-803
• Source: International Journal of Women's Dermatology, Vol 9, Iss 2, p e087 (2023)

Background:. Acquired vulvar lymphangioma (AVL) is not well-characterized. Diagnosis is delayed and the condition is often refractory to therapy. Objective:. The objective of this study was to provide a systematic review of AVL including risk factors, disease associations, and management options. Methods:. A primary literature search was conducted using 3 databases: PubMed, CINAHL, and OVID, from all years to 2022. Results:. In total, 78 publications with 133 patients (48 ± 17 years) were included. Most studies were case reports/series. The most common disease association was prior malignancy (70 patients, 53% of cases) and inflammatory bowel disease (6 patients, 5% of cases). The most common malignancy was cervical cancer (57 patients, 43% of cases). Most patients had prior radiation or surgery, with 36% (n = 48) treated with radiation, 30% (n = 40) with lymph node dissection, and 27% (n = 36) with surgical resection. Common presenting symptoms included discharge/oozing, pain, and pruritus. Most patients underwent surgical treatment for AVL with 39% treated with excision, 12% with laser therapy (the majority used CO2), and 11% with medical therapies. Most patients had failed prior therapies and there was a diagnostic delay. Limitations:. Retrospective nature. Most studies were limited to case reports and case series, with interstudy variability and result heterogeneity. Conclusion:. AVL is an underrecognized entity and should be considered in patients with a history of malignancy or radiation to the urogenital area. Treatment should include multidisciplinary care and address underlying lymphatic changes, manage any existing inflammatory conditions, and utilize skin-directed therapies and barrier agents while addressing symptoms of pruritus and pain. Prospective studies are needed to further characterize AVL and develop treatment guidelines.